Clinical Trial Update: Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma [Phase 2]

View source ↗

Summary

Phase II study evaluating the combination of durvalumab, doxorubicin, and ifosfamide in pulmonary sarcomatoid carcinoma (a form of non-small cell lung cancer) h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pulmonary Sarcomatoid Carcinoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• Durvalumab (durvalumab)
• IFOSFAMIDE (IFOSFAMIDE)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED